
    
      This study will evaluate evaluate in subjects with stable SCD the safety, pharmacokinetic
      profile, clinical pharmacology actions and clinical activities of two dosing regimens of
      Aes-103 (1000 mg four times daily in Cohort A and a higher or lower dose given once daily or
      up to four times daily in Cohort B) given for up to 28 days in adult subjects with stable SCD
      compared with subjects receiving placebo.
    
  